See the DrugPatentWatch profile for Barhemsys
What is Barhemsys and what does its mechanism of action target?
Barhemsys is a brand of amisulpride injection used to treat postoperative nausea and vomiting (PONV). Its mechanism of action centers on blocking dopamine D2 receptors in the brain’s emetic pathways, which reduces nausea and vomiting signals.
How does dopamine D2 receptor blockade stop nausea and vomiting?
Amisulpride is a dopamine receptor antagonist. By inhibiting dopamine D2 signaling, it dampens activity in the central circuits that control the vomiting reflex, which is why it can prevent or reduce PONV after anesthesia and surgery.
Why is dopamine signaling involved in PONV?
Dopamine is one of the neurotransmitters implicated in triggering the emetic response. Many antiemetic strategies work by reducing neurotransmitter signaling in brain regions that integrate nausea/vomiting inputs, and dopamine D2 blockade is one such approach.
How does Barhemsys compare with other antiemetics (different targets, different MOA)?
Barhemsys targets dopamine D2. Other common PONV drugs act on different receptors or pathways, such as 5-HT3 (serotonin) or NK1 (substance P), which is why clinicians sometimes combine agents with different mechanisms when trying to improve control of symptoms.
Does Barhemsys’ MOA affect anything beyond nausea and vomiting?
Because its antiemetic effect comes from dopamine D2 receptor antagonism, the same pathway is also the basis for dopamine-related effects and potential side effects seen across dopamine-blocking antiemetics, depending on dose and patient factors.
What should patients and clinicians watch for with dopamine D2 antagonists?
While Barhemsys’ goal is antiemetic control, dopamine D2 blockade can contribute to adverse effects typical of this drug class, so monitoring and risk assessment are tied to the dopamine receptor mechanism.
Sources:
1. https://www.accessdata.fda.gov